Indoco Remedies: UK MHRA inspection at Goa facility concludes with no critical observations

Indoco Remedies Limited announced that its manufacturing facility at Plant I in Goa, which produces solid oral dosage forms, underwent an inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) from September 7th to 9th, 2026. The inspection, conducted under current Good Manufacturing Practices (cGMP), concluded without any critical or major observations. This facility is crucial for supplying regulated markets like the UK, Europe, South Africa, New Zealand, Australia, and Canada, contributing approximately 30% to the company's total international business. The successful inspection validates Indoco's robust quality systems and commitment to global standards, reinforcing trust with international partners and enhancing its capacity to serve patients worldwide. The plant also holds approvals from USFDA, TGA-Australia, EU Malta, and WHO-GMP.